Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats

Xenobiotica

Volumn 38, Issue 2, 2008, Pages 147-155

  Kang, H J ^a,b   Song, I S ^a   Lee, S S ^a   Yoo, M A ^b   Shin, J G ^a  

^a Inje University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Cytochrome P450 (CYP); Dietary salt; Gene expression; Nuclear receptor; Transporter

Indexed keywords

CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN CAR; PROTEIN FXR; PROTEIN PXR; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; DUODENUM; GENE CONTROL; ILEUM; INTESTINE; JEJUNUM; KIDNEY; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALT INTAKE; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; ILEUM; KIDNEY; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY;

RATTUS;

EID: 38149075259     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701744674     Document Type: Article

References (36)

1. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernas H. 2007. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large intestine. Molecular Pharmacology 4:252-257.
2. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, De Waziers I. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2, and CYP3 families in 22 different human tissues. Pharmacogenetics and Genomics 17:731-742.
3. Carillo BA, Beutel A, Mirandola DA, Vidonho Jr AF, Furukawa LNS, Casarini D, Campo RR, Dolnikoff MS, Heimann JC, Bergamaschi CT. 2007. Differential sympathetic and angiotensinergic responses in rats submitted to low- or high-salt diet. Regulatory Peptides 140:5-11.
4. Culm-Merdek KE, Von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. 2006. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clinical Pharmacology and Therapeutics 79:243-254.
5. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. 2001. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 299:825-831.
6. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM. 1997. Dietary salt increases first-pass elimination of oral quinidine. Clinical Pharmacology and Therapeutics 61:292-300.
7. Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, Eichelbaum M, Roden DM. 1998. Modulation by dietary salt of verapamil disposition in humans. Circulation 98:2702-2708.
8. Ding X, Kaminsky LS. 2003. Human extrahepatic cytochrome P450: function in xenobiotic metabolism and tissue selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual Review of Pharmacology and Toxicology 43:149-173.
9. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. 2003. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology 95:1297-1300.
10. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. 2007. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clinical Pharmacology and Therapeutics 81:362-370.
11. Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J, Weimar W, Van Gelder T. 2003. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics 74:245-254.
12. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences, USA 97: 3473-3478.
13. Ito T, Asakura K, Tougou K, Fukuda T, Kubota R, Nonen S, Fujio Y, Azuma J. 2007. Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes. Molecular Pharmacology 72:173-181.
14. Kosuge K, Chuang AI, Uematsu S, Tan KP, Ohashi K, Ko BC, Ito S. 2007. Discovery of osmo-sensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5) molecular pharmacology 72:826-837.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Strom S, Thummel K, Boguski MS, Schuetz E. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27:383-391.
16. Lam AK, Ko BC, Tam S, Morris R, yang JY, Chung SK, Chung SS. 2004. Osmotic response element-binding protein (OREBP) is an essential regulator of the urine concentrating mechanism. Journal of Biological Chemistry 279:48048-48054.
17. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo WS, Watkins PB. 1997a. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. Journal Clinical Investigation 99:2545-2553.
18. Lown KS, Mayo RR, Leichtman AB, Hsaio H, Turgeon K, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997b. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics 62:248-260.
19. Martignoni M, Groothuis GM, De Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug metabolism and Toxicology 2:875-894.
20. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 75:13-33.
21. Matheny CJ, Ali RY, Yang X, Pollack GM. 2004. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metabolism and Disposition 32:1008-1014.
22. Morales MM, Capella MA, Sanches MV, Lopes AG, Guggino WB. 2000. Modulation of the mdr-1bgene in the kidney of rats subjected to dehydration or a high-salt diet. Pflugers Archiv 439:356-362.
23. Nebert DW, Russell DW. 2002. Clinical importance of the cytochrome P450. Lancet 360:1155-1162.
24. Ni XP, Humphreys MH. 2007. Prevention of salt-induced hypertension by an analog of γ-melanocyte-stimulating hormone in the rat. American Journal Hypertension 20:862-865.
25. O'Shaughnessy KM, Karet FE. 2006. Salt handling and hypertension. Annual Review of Nutrition 26:343-365.
26. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 283:1552-1562.
27. Reinehr R, Graf D, Fischer R, Schliess F, Haussinger D. 2002. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Hepatology 36:602-614.
28. Reinehr R, Schliess F, Haussinger D. 2003. Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB Journal 17:731-733.
29. Stiborová M, Borek-Dohalská L, Aimová D, Kotrbová V, Kukacková K, Janouchová K, Rupertová M, Ryslavá H, Hudecek J, Frei E. 2006. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. General Physiology and Biophysics 25:245-261.
30. Teixeira D, Sheth U, Valencia-Sanchez MA, Brengues M, Parker R. 2005. Processing bodies require RNA for assembly and contain nontranslating mRNAs. RNA 11:371-382.
31. Thomas FJ, McLeod HL, Watters JW. 2004. Pharmacogenomics: the influence of genomic variation on drug response. Current Topics in Medicinal Chemistry 4:1399-1409.
32. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. 2004. CYP3A variation and the evolution of salt-sensitivity variants. American Journal of Human Genetics 75:1059-1069.
33. + storage in rats. American Journal of Physiology Renal Physiology 285:F1108-F1117.
34. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 13:129-134.
35. Woo SK, Lee SD, Kwon HM. 2002. TonEBP transcriptional activator in the cellular response to increased osmolality. Pflugers Archiv 444:579-585.
36. Xu C, Li CY, Kong AN. 2005. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmaceutical Research 28:249-268.